CALT News and Press, Calliditas Therapeutics AB From 03/13/23

2023-03-13 08:54:26 ET Provention Bio PRVB +263% on ~$2.9B acquisition by Sanofi. Calliditas Therapeutics ( CALT ) +29% announces primary endpoint successfully Met in phase 3 NefIgArd trial evaluating Nefecon® in IgA Nephropathy. Caleminder ( CMND ...

Calliditas Announces Primary Endpoint Successfully Met in Phase 3 NefIgArd Trial Evaluating Nefecon® in IgA Nephropathy PR Newswire STOCKHOLM , March 13, 2023 /PRNewswire/ -- Calliditas Therapeutics AB (NASDAQ: CALT) (NASDAQ Stockholm: CALTX) ("Callidi...

Summary Calliditas Therapeutics is a commercial-stage biopharmaceutical company based in Sweden focused on developing and commercializing novel treatments for rare diseases. TARPEYO is the only disease-modifying therapy approved for IgAN. We expect TARPEYO's 2023 sales to be better ...

Calliditas Therapeutics press release ( NASDAQ: CALT ): Q4 GAAP loss of -SEK0.07 Revenue of SEK429M vs. SEK31.2M in 4Q21. For further details see: Calliditas Therapeutics reports Q4 results

Calliditas - Year-End Report, 2022 PR Newswire 2022: Successful transformation into a commercial stage company STOCKHOLM , Feb. 23, 2023 /PRNewswire/ -- "2022 was a fantastic year for Calliditas as we launched TARPEYO ® in the US, the first a...

Summary Sparsentan is approved for IgAN with a disappointing FDA label. We believe the approval is fully priced in, and we expect disappointing sales print during the first few years and fierce competition with Chinook's Atrasentan later on. Sparsentan is expected to launch in Feb 2...

Calliditas Therapeutics' ( OTCPK:CLTEF ) ( NASDAQ: CALT ) partner Everest Medicines said the Korea Ministry of Food and Drug Safety (MFDS) granted global innovative product on fast track (GIFT) designation to Nefecon to treat primary immunoglobulin A nephropathy (IgAN). ...

Calliditas Receives Conditional Marketing Authorization from UK MHRA for Kinpeygo in IgA nephropathy PR Newswire STOCKHOLM , Feb. 2, 2023 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas") today announced that...

Summary CALT has an approved product in the US and EU in IgAN. However, the rest of its pipeline consists of an unconvincing single product with a history of failure. They are also low on cash. Calliditas Therapeutics (CALT) is a small Swedish company that describes itself...

Summary Vera’s phase 2b ORIGIN data was underwhelming with lower than expected proteinuria reduction ~31% even at 9 months. We believe Atacicept’s commercial opportunity in IgAN is questionable due to the high degree of competition from KDNY, Otsuka, and Remegen. VERA ...